Polycystic Ovary SyndromeNCT03594968
Oxidative Stress in Polycystic Ovary Syndrome With Periodontal Disease and Dental Caries Lesions
An observational study of Polycystic Ovary Syndrome and Dental Caries, run by Recep Tayyip Erdogan University Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
This study evaluates the oxidative stress parameters in females with polycystic ovary syndrome (PCOS) and clinically healthy. Because of the fact that both oral disease included periodontitis and dental caries, and metabolic syndrome are associated with systemic inflammation, these two disorders may be linked through… Read more about this study
- Who is it for?
- Ages 18 to 24 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Polycystic Ovary Syndrome, Dental Caries
- What is being tested?
- polycystic ovary syndrome
- How many people
- 206 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Apr 2018to 15 May 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 24 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Patients were aged from 18 to 24 years, 206 females
Who may be able to join
- females with Polycystic Ovary Syndrome
Who cannot join
- history of ovarian surgery, patients with thyroid or prolactin hormone level abnormalities, non-classic 21-hydroxylase deficiency and hormonal therapy, steroid drug use past 6 months, obese patients (body mass index, BMI > 35), acute or chronic upper respiratory tract diseases, dental fluorosis, patients using fluoride supplements or orthodontic appliances will not be included in the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Polycystic Ovary Syndrome With Periodontal Disease and Dental Caries
This study evaluates the oxidative stress parameters in females with polycystic ovary syndrome (PCOS) and clinically healthy. Because of the fact that both oral disease included periodontitis and dental caries, and metabolic syndrome are associated with systemic inflammation, these two disorders may be linked through a common pathophysiologic pathway
Read the detailed description
Power analysis was performed with the G-Power software package to determine sample size. To cover possible data loss, 10% of a group were added to each group. Medical and dental examination will be performed both of control and experimental groups. Age and body mass index (BMI) will be recorded.
In dental examination decayed, missing, or filled teeth (DMFT) index will be used according to World Health Organization (WHO 1997) criteria. All teeth were visually using the International Caries Detection and Assessment System (ICDAS-II). To analyze the correlation between oral health status and polycystic ovary syndrome linear regression test and for comparison of both the groups (case and control), two sample t test and chi square test were used.
- Conditions
- Polycystic Ovary Syndrome, Dental Caries
- Being tested
- polycystic ovary syndrome
- Medical subject headings
- Polycystic Ovary Syndrome, Dental Caries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
polycystic ovary syndromeDiagnostic test
Also called [LH],, [total T],, [free T],, [DHEA-S],
3 to 5th day of the women's normal cycle, we will perform a routine gynecological examination, a basic vaginal ultrasound, a basal hormone profile evaluation
| Study group | Role | What they receive |
|---|---|---|
| polycystic ovary syndrome (PCOS) | Presence of ≥2 of the following:
1. oligomenorrhea and/or anovulation
2. Hyperandrogenism (clinical and/or biochemical) One of the signs for clinical hyperandrogenism is hirsutism, which represents hair growth in a male pattern on a female with four different degrees of severity in 11 different body parts: 1) upper lip; 2) chin; 3) chest; 4) upper back; 5) lower back; 6) upper abdomen; 7) lower abdomen; 8) arm; 9) forearm; 10) thigh; and 11) lower leg. The Ferriman-Gallwey scoring system is used to score the degree of excess male-pattern body hair to indicate hirsutism. Receives: Diagnostic Test: polycystic ovary syndrome | |
| healthy | healthy patients who had no polycystic ovary Receives: Diagnostic Test: polycystic ovary syndrome |
What is being measured
The primary outcome is the main question the study is designed to answer.
FSH hormone ovarian morphology (PCOM)
follicle-stimulating hormone [FSH] is tested by blood sample 6.3_24 mlu/ml
Measured: 1 Day
luteinizing hormone
luteinizing hormone [LH] is tested by blood sample 1.68-15 U/L
Measured: 1 day
dehydroepiandrosterone-sulfate
dehydroepiandrosterone-sulfate [DHEA-S] is tested by blood sample 65 to 380 µg/dL or 1.75 to 10.26 µmol/L
Measured: 1 day
17-OH-progesterone
17-OH-progesterone is tested by blood sample 20-100 ng/dL
Measured: 1 day
Secondary outcomes (6)
dental examination
All teeth were visually using the International Caries Detection and Assessment System (ICDAS-II). The chosen sites were recorded as: 0 = sound;
- = first visible sign of noncavitated lesion seen only when the tooth is dried;
- = visible noncavitated lesion seen when wet and dry;
- = microcavitation in enamel;
- = noncavitated lesion extending into dentine seen as an undermining shadow;
- = small cavitated lesion with visible dentine: less than 50% of surface;
- = large cavitated lesions with visible dentine in more than 50% of the surface.
Measured: 1 Day
periodontal examination
A single calibrated examiner measured probing depth-PD, 0: healthy
bleeding calculus 3:3.5-5.5 mm 4: over 5.5 mm
Measured: 1 Day
Clinical attachment level
A single calibrated examiner measured clinical attachment level- CAL, 0: 0-3 mm 1:4-5 mm 2:6-8 mm 3:over 8mm 4: 9-11 mm 5: over 12 mm
Measured: 1 Day
Plaque Examination
The plaque amount is scored by using Silness\&Löe Plaque Index Each of the four surfaces of the teeth (buccal, lingual, mesial and distal) is given a score from 0-3.
0:no plaque
- A film of plaque
- soft deposit s within the gingival pocket
- Abundance of soft matter within the gingival pocket.
Calculation: Total scores of 6 (16, 12, 24, 36, 32, 44) teeth / No of surfaces examined
Healthy = PI<0.4. Mild = PI 0.4-1.0. Moderate = PI 1.1-2. Severe = PI>2.
Measured: 1 Day
Gingival Examination
0= Normal gingiva;
- Mild inflammation
- Moderate inflammation
- Severe inflammation Calculation: Total scores/ no of surfaces examined 0.1-1:Mild gingivitis, 1.1-2:moderate gingivitis; 2.1-3:severe gingivitis
Measured: 1 Day
Bleeding Examination
0: no bleeding
1: bleeding
Measured: 1 Day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2018
- Study start15 Apr 2018
- Primary completion30 Mar 2019
- Study completion15 May 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Polycystic Ovary SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 206 participants (actual)
Sponsor and investigators
- Lead sponsor
- Recep Tayyip Erdogan University Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gul Yildiz Telatar, Recep Tayyip Erdogan University Training and Research Hospital
- Investigators
- Gül Yıldız Telatar, Principal investigator, Recep Tayyip Erdogan University Dentistry Faculty
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03594968
- Sponsor's protocol ID
- 40986104-799
- Status last verified
- Sep 2021
- First submitted
- 10 Jul 2018
- Last updated
- 9 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data will be available within 6 months of study finishing
Publications
Ozcaka O, Ceyhan BO, Akcali A, Bicakci N, Lappin DF, Buduneli N. Is there an interaction between polycystic ovary syndrome and gingival inflammation? J Periodontol. 2012 Dec;83(12):1529-37. doi: 10.1902/jop.2012.110588. Epub 2012 Apr 17.
PubMed 22509751
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Polycystic Ovary Syndrome With Periodontal Disease and Dental Caries
- ClinicalTrials.gov ID
- NCT03594968
- Acronym / sponsor ID
- 40986104-799
- Conditions
- Polycystic Ovary Syndrome, Dental Caries
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 206 participants (actual)
- Lead sponsor
- Recep Tayyip Erdogan University Training and Research HospitalUniversity, hospital or other
- Study start
- 15 Apr 2018 (actual)
- Primary completion
- 30 Mar 2019 (actual)
- Study completion
- 15 May 2019 (actual)
- First posted
- 20 Jul 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the oxidative stress parameters in females with polycystic ovary syndrome (PCOS) and clinically healthy. Because of the fact that both oral disease included periodontitis and dental caries, and metabolic syndrome are associated with systemic inflammation, these two disorders may be linked through a common pathophysiologic pathway
Detailed description
Power analysis was performed with the G-Power software package to determine sample size. To cover possible data loss, 10% of a group were added to each group. Medical and dental examination will be performed both of control and experimental groups. Age and body mass index (BMI) will be recorded.
In dental examination decayed, missing, or filled teeth (DMFT) index will be used according to World Health Organization (WHO 1997) criteria. All teeth were visually using the International Caries Detection and Assessment System (ICDAS-II). To analyze the correlation between oral health status and polycystic ovary syndrome linear regression test and for comparison of both the groups (case and control), two sample t test and chi square test were used.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| polycystic ovary syndrome (PCOS) | – | Diagnostic Test: polycystic ovary syndromePresence of ≥2 of the following: 1. oligomenorrhea and/or anovulation 2. Hyperandrogenism (clinical and/or biochemical) One of the signs for clinical hyperandrogenism is hirsutism, which represents hair growth in a male pattern on a female with four different degrees of severity in 11 different body parts: 1) upper lip; 2) chin; 3) chest; 4) upper back; 5) lower back; 6) upper abdomen; 7) lower abdomen; 8) arm; 9) forearm; 10) thigh; and 11) lower leg. The Ferriman-Gallwey scoring system is used to score the degree of excess male-pattern body hair to indicate hirsutism. |
| healthy | – | Diagnostic Test: polycystic ovary syndromehealthy patients who had no polycystic ovary |
Who may qualify
- Ages
- 18 to 24 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Patients were aged from 18 to 24 years, 206 females
Key inclusion criteria (1 listed)
- females with Polycystic Ovary Syndrome
Key exclusion criteria (1 listed)
- history of ovarian surgery, patients with thyroid or prolactin hormone level abnormalities, non-classic 21-hydroxylase deficiency and hormonal therapy, steroid drug use past 6 months, obese patients (body mass index, BMI > 35), acute or chronic upper respiratory tract diseases, dental fluorosis, patients using fluoride supplements or orthodontic appliances will not be included in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| polycystic ovary syndromeAlso: [LH],, [total T],, [free T],, [DHEA-S],3 to 5th day of the women's normal cycle, we will perform a routine gynecological examination, a basic vaginal ultrasound, a basal hormone profile evaluation | Diagnostic test | healthy, polycystic ovary syndrome (PCOS) |
Primary outcome
FSH hormone ovarian morphology (PCOM)
Time frame: 1 Day
follicle-stimulating hormone [FSH] is tested by blood sample 6.3_24 mlu/ml
luteinizing hormone
Time frame: 1 day
luteinizing hormone [LH] is tested by blood sample 1.68-15 U/L
dehydroepiandrosterone-sulfate
Time frame: 1 day
dehydroepiandrosterone-sulfate [DHEA-S] is tested by blood sample 65 to 380 µg/dL or 1.75 to 10.26 µmol/L
17-OH-progesterone
Time frame: 1 day
17-OH-progesterone is tested by blood sample 20-100 ng/dL
6 secondary outcomes
dental examination
Time frame: 1 Day
periodontal examination
Time frame: 1 Day
Clinical attachment level
Time frame: 1 Day
Plaque Examination
Time frame: 1 Day
Gingival Examination
Time frame: 1 Day
Bleeding Examination
Time frame: 1 Day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2021.
- Background: PubMed 22509751Ozcaka O, Ceyhan BO, Akcali A, Bicakci N, Lappin DF, Buduneli N. Is there an interaction between polycystic ovary syndrome and gingival inflammation? J Periodontol. 2012 Dec;83(12):1529-37. doi: 10.1902/jop.2012.110588. Epub 2012 Apr 17.
- Polycystic Ovary Syndrome and Gingival InflammationLink provided by the sponsor.
- Individual participant dataSharing planned: No. Data will be available within 6 months of study finishing
Related trials for Polycystic Ovary Syndrome
Recruiting
Efficacy of Ovarian Drilling Via vNOTES Laparoscopy in Patients With PCOS
PCOS (Polycystic Ovary Syndrome)
RecruitingPhase 1
Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome
Anovulatory Infertility
RecruitingObservational study
The Value of LC-MS/MS Detection of Androgen Profiles in the Diagnosis of PCOS: A Prospective, Multicenter Real-world Study
Polycystic Ovary Syndrome (PCOS)
Recruiting
The Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome
PCOS (Polycystic Ovary Syndrome)
Recruiting
Brown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography
Polycystic Ovary Syndrome (PCOS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gül Yıldız Telatar principal investigator
Recep Tayyip Erdogan University Dentistry Faculty
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Polycystic Ovary Syndrome and Dental Caries, run by Recep Tayyip Erdogan University Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
FSH hormone ovarian morphology (PCOM) (time frame: 1 Day). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03594968, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2021.